Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Counterfeit Harvoni Discovered in Nara Pharmacy, MHLW Investigating Route of Entry into Distribution
Counterfeits of Gilead Sciences’s hepatitis C treatment Harvoni Combination Tablets (ledipasvir + sofosbuvir) have been discovered at a pharmacy chain in Nara Prefecture, the Ministry of Health, Labor and Welfare (MHLW) revealed on January 17. The MHLW issued a notification…
To read the full story
Related Article
- Wholesale Dealer President Deeply Sorry for Letting Fake Harvoni into Supply Chain
March 24, 2017
- 2 Kansai Medico Pharmacy Outlets Ordered to Suspend Biz
March 17, 2017
- 3 Kansai Medico Pharmacies Slapped with Biz Improvement Order over Fake Harvoni
March 7, 2017
- MHLW Mulls Administrative Penalties, Tighter Regulations after Counterfeit Harvoni Case
February 14, 2017
- MHLW Wraps Up Probe into Fake Harvoni after Distribution Routes “Most Likely” Identified
February 2, 2017
- MHLW Pins Down Distribution Routes for Harvoni Counterfeits; Composition of Fake Pills Identified
February 1, 2017
- MHLW Warns Against Purchasing Harvoni in Unpackaged Bottles
January 26, 2017
- Kansai Medico Used Non-Official Harvoni Dealer for Cheaper Price
January 25, 2017
- Kansai Medico Issues Apology over Harvoni Counterfeits
January 24, 2017
- Counterfeit Harvoni Found in Tokyo Too, Route Identified for a Nara Bottle
January 24, 2017
- MHLW Asks Pref. Govt to Conduct On-Site Inspections for Pharmacies, Wholesalers: Minister
January 23, 2017
- Counterfeit Harvoni Likely Entered Distribution before Reaching Pharmacies: MHLW Official
January 23, 2017
- NPhA Instructing Member Pharmacies on Careful Drug Purchases after Fake Harvoni Issue: Chief
January 20, 2017
- We Must Redouble Efforts for Proper Drug Distribution, Pharmacist Group Says on Fake Harvoni Issue
January 19, 2017
- Gilead Japan to Switch Sovaldi, Harvoni Bottles to Blister Packs
January 19, 2017
- Gilead Asks Pharmacists to Open Harvoni Bottles in Front of Patients after Fake Drug Found
January 18, 2017
REGULATORY
- Japan Officially Eases Trial Recruitment Rules; Industry Welcomes Move
April 1, 2026
- MHLW Updates Q&A on Use of Registry Data in Drug Applications
April 1, 2026
- Japan Panel Designates Two Ebola Therapies for Early Approval Pathway
April 1, 2026
- MHLW, METI Launch Joint Task Force to Safeguard Medical Supply Chains
April 1, 2026
- Japan Urges Priority Supply of Petroleum-Based Materials for Medical Devices
March 31, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…